Clinical Trials Logo

Filter by:
NCT ID: NCT01034163 Completed - Hodgkin's Lymphoma Clinical Trials

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma

PATH
Start date: June 2010
Phase: Phase 3
Study type: Interventional

The purpose of this phase III study is to evaluate the efficacy of orally-administered panobinostat in reducing the risk of relapse in patients with classical Hodgkin's Lymphoma who achieved a complete response following high-dose chemotherapy (HDT) with Autologous stem cell transplant(AHSCT).

NCT ID: NCT01033734 Completed - Influenza Clinical Trials

A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza

Start date: December 2010
Phase: Phase 1
Study type: Interventional

This open-label study will assess the pharmacokinetics/pharmacodynamics and safety of intravenous (iv) Tamiflu (oseltamivir) in 3 cohorts of children, aged 6-12, 3-5 and 1-2 years, with influenza infection. Patients will receive iv Tamiflu therapy for 5 days (10 doses). For patients whose conditions no longer merit continued iv dosing, therapy may be switched to oral Tamiflu to complete their prescribed course of treatment. If medically necessary, iv or oral therapy with Tamiflu may be continued for up to 5 additional days. Anticipated time on study treatment is 5 to 10 days.

NCT ID: NCT01033448 Completed - Clinical trials for Hepatitis C, Chronic

A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response

Start date: December 2009
Phase: Phase 4
Study type: Interventional

This open-label, multi-center study will evaluate the safety and tolerability and the effect on viral activity of a combined PEGASYS and COPEGUS extended therapy in patients with chronic hepatitis C with genotype 1, 2 and 3. Patients who completed 48 weeks (genotype 1) or 24 weeks (genotype 2 and 3) of standard treatment with PEGASYS and COPEGUS and were identified as slow virological responders will be enrolled in this study in order to receive additional 24 weeks of treatment. PEGASYS 180 micrograms will be administered sc once weekly and COPEGUS will be administered as 800 mg, or 1000-1200 mg daily oral doses. The anticipated time on study treatment is 24 weeks. The target sample size is 50-150 patients.

NCT ID: NCT01033435 Completed - Inflammation Clinical Trials

The Influence of Cessation of Pomegranate Juice Intake on Inflammation and Oxidative Stress Markers and Glucose Control in Diabetic and Non Diabetic Chronic Hemodialysis Patients

Start date: December 2009
Phase: N/A
Study type: Observational

The current study will investigate chronic hemodialysis patients who were treated in our unit with pomegranate juice intake for 1 year - compared to a control group. Markers will be taken 3 months after cessation of pomegranate juice intake, for inflammation and oxidative stress and Hb A1c.

NCT ID: NCT01033422 Completed - Glaucoma Clinical Trials

Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure

Start date: October 2010
Phase: Phase 2
Study type: Interventional

This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma. Eligible patients with elevated intraocular pressure will be evaluated and treated by ophthalmologist investigators, and will receive either CF101 pills or placebo (dummy) pills twice daily for 16 weeks. Ocular pressure, visual fields, and other aspects of safety and effectiveness will be monitored on a regular basis.

NCT ID: NCT01032915 Terminated - Clinical trials for Non-infectious Uveitis

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

ENDURE
Start date: February 2010
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.

NCT ID: NCT01032785 Recruiting - Clinical trials for Closure of the Foramen Ovale and Ductus Arteriosus

Timing of Closure of Patent Foramen Ovale Following Birth

Start date: December 2009
Phase: N/A
Study type: Observational

It is known that the foramen ovale closes in most infants during the first 6 months of life, however, most of the important papers in the field concentrated on observing infants with murmurs and following those with patent foramen ovale by echocardiography until 6-24 months. The purpose of this study is to observe the natural profile of closure of the foramen ovale and ductus arteriosus for the first 36 hours after birth. This understanding may help to avoid unnecessary treatment and exams for newborns with findings that are natural for their stage of development.

NCT ID: NCT01032629 Completed - Clinical trials for Diabetes Mellitus, Type 2

CANVAS - CANagliflozin cardioVascular Assessment Study

CANVAS
Start date: December 9, 2009
Phase: Phase 3
Study type: Interventional

The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin. The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.

NCT ID: NCT01032369 Not yet recruiting - Obesity Clinical Trials

The Additive Effect of Cognitive Behavioral Treatment (CBT) to Conventional Weight Loss Intervention Program for Young Adults With Intellectual Disabilities

Start date: December 2009
Phase: N/A
Study type: Interventional

In this randomized case control study we will evaluate the additive effect of psychological intervention, i.e CBT-cognitive behavioral treatment in a multi-strategy weight loss program composed of physical activity intervention and nutritional programme.

NCT ID: NCT01029977 Withdrawn - Breast Cancer Clinical Trials

Imaging Modality Effects on the Multi-dimensional InfraRed Analysis (MIRA) Technology

Start date: May 2015
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the effect of everyday practice modalities (mammography, US) on the MIRA technology.